Respiratory chain gene mutations associated with global phylogenetic clustering of drug-resistant Mycobacterium tuberculosis revealed by whole-genome sequencing - Scorecard - MDSpire
Advertisement
Respiratory chain gene mutations associated with global phylogenetic clustering of drug-resistant Mycobacterium tuberculosis revealed by whole-genome sequencing
Clinical Scorecard: Gene Mutations in the Respiratory Chain Linked to Phylogenetic Grouping of Drug-Resistant Mycobacterium tuberculosis Identified Through Whole-Genome Sequencing
At a Glance
Category
Detail
Condition
Multidrug-resistant tuberculosis (MDR-TB)
Key Mechanisms
Gene mutations in the respiratory chain affecting drug resistance and phylogenetic clustering.
Target Population
Individuals diagnosed with M. tuberculosis infection, particularly in high-incidence areas.
Care Setting
Clinical research settings in high-incidence regions.
Key Highlights
30.09% of analyzed M. tuberculosis isolates were multidrug-resistant.
Specific SNPs in respiratory chain genes were linked to MDR isolate clustering.
Whole-genome sequencing is crucial for understanding MDR-TB transmission.
Guideline-Based Recommendations
Diagnosis
Use whole-genome sequencing for accurate identification of drug-resistant M. tuberculosis.
Management
Consider the role of respiratory chain gene mutations in treatment planning for MDR-TB.
Monitoring & Follow-up
Regular genomic surveillance of M. tuberculosis isolates to track mutations and resistance patterns.
Risks
Increased risk of MDR-TB transmission due to respiratory chain gene mutations.
Patient & Prescribing Data
Individuals with confirmed M. tuberculosis infection, excluding those on treatment or with severe comorbidities.
Bedaquiline and pretomanid are FDA-approved for treating MDR-TB.
Clinical Best Practices
Implement genomic sequencing in clinical settings to guide MDR-TB management.
Educate healthcare providers on the implications of respiratory chain mutations in TB treatment.
